Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

BackgroundCell line models have proven to be effective tools to investigate a variety of ovarian cancer features. Due to the limited number of cell lines, particularly of the serous subtype, the heterogeneity of the disease, and the lack of cell lines that model disease progression, there is a need to further develop cell line resources available for research. This study describes nine cell lines derived from three ovarian cancer cases that were established at initial diagnosis and at subsequent relapse after chemotherapy.MethodsThe cell lines from three women diagnosed with high-grade serous ovarian cancer (1369, 2295 and 3133) were derived from solid tumor (TOV) and ascites (OV), at specific time points at diagnosis and relapse (R). Primary treatment was a combination of paclitaxel/carboplatin (1369, 3133), or cisplatin/topotecan (2295). Second line treatment included doxorubicin, gemcitabine and topotecan. In addition to molecular characterization (p53, HER2), the cell lines were characterized based on cell growth characteristics including spheroid growth, migration potential, and anchorage independence. The in vivo tumorigenicity potential of the cell lines was measured. Response to paclitaxel and carboplatin was assessed using a clonogenic assay.ResultsAll cell lines had either a nonsense or missense TP53 mutations. The ability to form compact spheroids or aggregates was observed in six of nine cell lines. Limited ability for migration and anchorage independence was observed. The OV3133(R) cell line, formed tumors at subcutaneous sites in SCID mice. Based on IC50 values and dose response curves, there was clear evidence of acquired resistance to carboplatin for TOV2295(R) and OV2295(R2) cell lines.ConclusionThe study identified nine new high-grade serous ovarian cancer cell lines, derived before and after chemotherapy that provides a unique resource for investigating the evolution of this common histopathological subtype of ovarian cancer.

[1]  David C. Corney,et al.  Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.

[2]  P. Kenemans,et al.  CA 125: fundamental and clinical aspects. , 1999, Seminars in cancer biology.

[3]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[4]  C. Le Page,et al.  Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. , 2007, Neoplasia.

[5]  R. Kennedy,et al.  BRCA1 and implications for response to chemotherapy in ovarian cancer. , 2009, Gynecologic oncology.

[6]  A. Mes-Masson,et al.  Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes , 2008, Molecular carcinogenesis.

[7]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[8]  A. Dueñas-González,et al.  Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. , 2006, Cancer treatment reviews.

[9]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[10]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[11]  J. Prat.  Ovarian carcinomas, including secondary tumors: diagnostically challenging areas , 2005, Modern Pathology.

[12]  F. Oesch,et al.  Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. , 1999, Cancer research.

[13]  G. Scambia,et al.  Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. , 2008, Gynecologic oncology.

[14]  B. Têtu,et al.  Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. , 2006, International journal of oncology.

[15]  R. Drapkin,et al.  The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.

[16]  R. Ozols,et al.  Challenges for chemotherapy in ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[18]  G. Mills,et al.  Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Mes-Masson,et al.  Characterization of three new serous epithelial ovarian cancer cell lines , 2008, BMC Cancer.

[20]  P. Kruk,et al.  A simplified method to culture human ovarian surface epithelium. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[21]  R. Bast,et al.  Serum levels of HER‐2 neu (C‐erbB‐2) correlate with overexpression of p185neu in human ovarian cancer , 1993, Cancer.

[22]  T. Herzog.  Recurrent Ovarian Cancer , 2004, Clinical Cancer Research.

[23]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[24]  E. Oliva,et al.  Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  C. Le Page,et al.  Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. , 2010, Translational oncology.

[26]  T. Tot.  Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. , 2002, European journal of cancer.

[27]  A. Schauer,et al.  Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. , 1994, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[28]  A. Mes-Masson,et al.  Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A , 2004, Cancer Chemotherapy and Pharmacology.

[29]  J. Lundin,et al.  Distinct subtypes of serous ovarian carcinoma identified by p53 determination. , 2003, Gynecologic oncology.

[30]  A. Mes-Masson,et al.  Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer , 2009, Molecular carcinogenesis.

[31]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[32]  C. Greenwood,et al.  Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations , 2004, International journal of cancer.

[33]  Bernard Têtu,et al.  Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. , 2006, International journal of oncology.

[34]  T. Hudson,et al.  Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.

[35]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  A. Mes-Masson,et al.  Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. , 1994, Experimental cell research.

[37]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.

[38]  P. Disaia,et al.  Radiation therapy for gynecologic cancer , 2002, The journal of obstetrics and gynaecology research.

[39]  Gordon B. Mills,et al.  Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites , 1999, Annals of Surgical Oncology.

[40]  A. Mes-Masson,et al.  Characterization of four novel epithelial ovarian cancer cell lines , 2000, In Vitro Cellular & Developmental Biology - Animal.

[41]  M. Červinka,et al.  Chemoresistance testing of human ovarian cancer cells and its in vitro model. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[42]  A. Mes-Masson,et al.  Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis , 2006, Oncogene.

[43]  Anne-Marie Mes-Masson,et al.  Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.

[44]  B. Vanderhyden,et al.  Models of ovarian cancer—Are we there yet? , 2005, Molecular and Cellular Endocrinology.

[45]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[46]  A. Mes-Masson,et al.  Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p , 2007, Oncogene.

[47]  Thomas J. Hardcastle,et al.  Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.

[48]  Anne-Marie Mes-Masson,et al.  Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC) , 2007, Molecular carcinogenesis.

[49]  A. Gadducci,et al.  Surveillance of patients after initial treatment of ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[50]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.